MedTrace Logo

Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing

NCT03166618 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2018-10-18

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and effectiveness of JUVÉDERM VOLUMA XC injectable gel in adult participants seeking correction of temple hollowing.

Conditions

  • Temple Hollowing

Interventions

DEVICE

Juvéderm® VOLUMA XC

Juvéderm® VOLUMA XC hyaluronic acid injectable gel

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Nikki Amaratunge · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-24
Primary Completion
2017-07-21
Completion
2017-07-21
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03166618 on ClinicalTrials.gov